Key result
Heart failure affects approximately 26 million patients worldwide, and this review summarizes global trends, costs, and the growing utilization of mechanical circulatory support.
Why the study?
Heart failure prevalence, morbidity, mortality, and management statistics differ globally, requiring review of trends, costs, and mechanical circulatory support utilization.
This review provides an overview of the epidemiology, economic burden, and utilization of mechanical circulatory support for heart failure in 2020.
Answers are grounded in this paper and cite their sources.
Underscores the global heart failure burden and rising mechanical support use; extends epidemiological summaries for guiding future research priorities.
Heart failure is increasing in prevalence, with approximately 26 million patients affected worldwide. This represents a significant cause of morbidity and mortality. Statistics regarding heart failure patient age, hospitalization likelihood, and mortality differ significantly by country. Heart failure patients are typically classified by ejection fraction, with distinct phenotypes associated with reduced ejection fraction (rEF) or preserved ejection fraction (pEF). Heart failure has a significant financial impact related to hospitalization, medication, and procedural expenses. The costs of heart failure also extend to the reduced quality of life conferred by heart failure symptoms. Management of heart failure includes a variety of interventions, including mechanical circulatory support (MCS). MCS, including left ventricular assist devices (LVADs), right ventricular assist devices (RVADs) and extracorporeal membrane oxygenation (ECMO), has been a means of managing end stage heart failure. Given the relative scarcity of transplant organs, the utilization of MCS, particularly as a bridge to transplantation (BTT) has grown significantly. In this review, we discuss statistics related to heart failure and MCS. We evaluate how patients are classified and examine global trends and regional differences. We then address MCS therapies, the costs associated with heart failure, the impact of heart failure on patient quality of life, and data regarding morbidity and mortality.
No takes yet. Share an insight, caveat, or question.
Bowen et al. (2020) conducted a review in Heart failure. Mechanical circulatory support was evaluated. Heart failure affects approximately 26 million patients worldwide, and this review summarizes global trends, costs, and the growing utilization of mechanical circulatory support.
Synapse has enriched 10 related papers. Consider them for comparative context: